Skip to content
DE

GLOW and KLOW: peptide blends, research, and unanswered questions

Clinical review pending

GLOW combines GHK-Cu, BPC-157, and TB-500; KLOW adds KPV. What component studies show, why blends need their own evidence, and what the October 2026 US policy changes.

A balance holds a bead chain on one side and a clear lens on the other.

GLOW and KLOW are marketed as injectable peptide blends. Interest in them comes largely from studies of individual ingredients in skin, wound healing, and tissue repair. The research discussed here does not establish a clinical benefit of either complete blend in humans. To understand what it does show, it helps to ask which substance was tested and whether the findings came from cells, animals, or people.

This article is for information and education. GLOW and KLOW are not FDA-approved medicines. The regulatory section below distinguishes approval of a drug from the rules governing pharmacy compounding. This article does not replace medical advice, diagnosis, or treatment; health questions belong in a conversation with a qualified healthcare professional.

Key points

  • GLOW combines GHK-Cu, BPC-157, and TB-500 in an injectable blend. KLOW adds KPV to those three ingredients.
  • The ingredients have been studied separately, mostly in cell cultures and animal models. The literature cited here contains no human trial of either complete blend.
  • Approval, compounding-list status, and enforcement discretion are separate. An HHS policy announced on October 30, 2026, concerns certain single-ingredient peptides under specified conditions. It does not cover GLOW or KLOW as multi-ingredient blends.
  • Products sold under these names can carry research-use labeling, including “not for human use.” That wording is not a quality certification or permission to inject the product.
  • Baseline blood tests can describe liver and kidney function and blood cell counts. They do not directly measure whether a peptide is working.

What is the GLOW peptide blend?

GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500. Vendors and clinic websites use the name for this combination. Each ingredient is a separate compound with its own research history.

The name does not identify a single molecule or a standardized formulation defined by a regulator, a pharmacopoeia, or a clinical trial. Doses, ingredient ratios, and purity can therefore vary between suppliers. Most of the research can be understood only by looking at the ingredients individually.

GLOW and KLOW: what is the difference?

KLOW adds KPV to the ingredients in GLOW, bringing the total to four peptides. KPV is a short peptide that the FDA has considered among substances proposed for compounding. Its regulatory position is discussed below. The other three ingredients are shared by both blends.

Adding KPV introduces another compound whose properties remain incompletely understood. The unanswered questions about GLOW therefore also matter for KLOW. This does not mean the blends behave identically in the body. Because the cited literature does not study either complete mixture, it also provides no basis for calling KLOW an improved version.

GHK-Cu: the copper tripeptide

GHK-Cu consists of glycyl-L-histidyl-L-lysine bound to copper. Of the three GLOW ingredients, it has the longest research history. An early 1973 paper reported that a synthetic tripeptide increased the survival of normal liver cells. That finding belongs to the early history of GHK; it should not be presented as a trial of injected GHK-Cu. A 2008 review of tissue remodeling brought together the research that followed. Source Source

Most skin-related findings come from experiments outside the body, known as in vitro studies, or from animal models. In a wound-chamber experiment in rats, GHK-Cu increased collagen accumulation in a concentration-dependent manner. The amount of messenger RNA for types I and III collagen also increased. Messenger RNA carries the genetic instructions used to make these structural proteins. Source

In rats with ischemic wounds—wounds with an inadequate blood supply—a topical GHK-Cu gel reduced wound area by 64.5% by day 13. The reduction was 45.6% with the gel base alone and 28.2% in untreated wounds. A 2018 review added findings on gene expression and the signaling pathways influenced by GHK. These findings describe cellular changes; they do not directly demonstrate a benefit in people. Source Source

The limited human data discussed here concern topical use. In a randomized study of a copper tripeptide applied after CO₂ laser skin resurfacing, 13 people completed follow-up. Objective assessments found no statistically significant between-group differences in redness, wrinkles, or overall skin quality. Participants using GHK-Cu did, however, report greater improvement in their skin quality. A 2025 review of topical GHK described clinical studies as surprisingly scarce and skin penetration as an unresolved issue. None of these studies tested injected GHK-Cu. Source Source

BPC-157: the gastric-juice-derived pentadecapeptide

BPC-157 is a synthetic peptide consisting of 15 amino acids. Early reports described it as a fragment of a larger protein isolated from human gastric juice. “Pentadecapeptide” simply means a peptide made of 15 amino acids. In early rat ulcer models, the original research group reported protection against tissue damage caused by stress, cysteamine, and ethanol. The same group proposed that this 15-amino-acid fragment was important to the activity of the larger protein. Source Source

Proposed mechanisms mainly involve blood vessels and connective tissue. In isolated rat aortas, BPC-157 produced vasodilation that depended on the vessel lining and involved nitric oxide signaling. Another experiment linked BPC-157 to greater activity or expression of the VEGFR2 receptor and the growth of new blood vessels. That work used chicken embryos, rat hind limbs, and cultured human endothelial cells—the cells lining blood vessels. Source Source

In cultured rat tendon fibroblasts, BPC-157 increased phosphorylation of the proteins FAK and paxillin. Phosphorylation means that phosphate groups are attached to a protein. This chemical change forms part of a signaling pathway associated with cell migration. These proposed mechanisms come from animal and cell experiments; the cited studies do not confirm them in people. Source

Human evidence is very limited. A 2025 systematic review in orthopedic sports medicine included 36 studies: 35 preclinical investigations and one clinical report, with no controlled human trial in that review. The clinical report reviewed the records of 17 people who received knee injections; 16 could be reached by telephone. Twelve of those 16 received BPC-157 alone, while four received BPC-157 with thymosin beta-4. Pain was assessed by telephone rather than a controlled comparison. Without a control group, the report cannot reliably establish how much the treatment contributed to any improvement. Source Source

The same review reported a half-life of less than 30 minutes based on animal studies. Half-life is the time it takes for a concentration to fall by half. Its registry search found one human trial, a Phase I study with unknown status; that describes the review’s search, not a complete current inventory of clinical research. An independent 2019 review had already noted that few research groups had studied BPC-157 in depth, largely in small rodent models. Source

TB-500: the thymosin beta-4 fragment

Thymosin beta-4 is a protein made of 43 amino acids. A 2005 review described how it binds actin, influencing its availability, and discussed its roles in tissue repair. Actin is an important part of the cell’s internal structural framework. Source

The TB-500 fragment characterized in the cited analytical research is not the whole protein. It is an acetylated copy of amino acid positions 17 through 23: a chemically modified segment of thymosin beta-4. This region is associated with actin binding, cell migration, and wound repair. Doping-control laboratories characterized the fragment in TB-500 in 2012 because of suspected use in sport. One laboratory developed a test to detect its use in horses. Commercial naming is inconsistent, so a product name alone does not establish which molecule a vial contains. Source Source

A 2003 mouse study provides one starting point for research on this fragment. Full-length thymosin beta-4 accelerated skin wound healing in diabetic and aged mice. A seven-amino-acid peptide reproducing its actin-binding region promoted repair in the aged mice. This helps explain the research interest, but it does not demonstrate a benefit in humans. A 2010 review attributed different activities of thymosin beta-4 to several active regions within short amino acid sequences. The TB-500 fragment contains only one of them. Source Source

Some of the more substantial animal findings concern the complete protein. Full-length thymosin beta-4 improved heart function in mice after a coronary artery was tied off. A later experiment in mice and pigs attributed support for cardiac function after ischemia to the C-terminal AGES domain. That region at the end of the protein is absent from the TB-500 fragment. Source Source

The clinical trial discussed here also tested the full protein: a study of thymosin beta-4 eye drops in 18 people narrowly missed its primary endpoint. The prespecified main outcome was therefore not statistically significant, although some secondary measures favored the active eye drops. A 2026 scoping review—a review that maps an area of research—concluded that the human studies it assessed did not support claims of musculoskeletal benefit from TB-500 and related peptides. Source Source

What does research show about the blend itself?

The literature used for this article contains neither an animal study nor a human trial of GHK-Cu, BPC-157, and TB-500 given together. It also identifies no investigation of all three combined with KPV. The closest cited experiment is a 2026 rat study of Achilles tendon healing that tested BPC-157 and a product labeled TB-500. Combining the two did not add benefit over either alone. The paper identifies a commercial supplier but does not clearly establish the peptide sequence in its methods; this also limits comparison with research on a specifically defined fragment. Source

Most findings described above come from animal models or cell cultures. The human data cited here consist of small topical GHK-Cu skin studies, including one without an objectively measured advantage; an uncontrolled knee-injection report with 16 telephone respondents, some receiving two peptides; and eye-drop studies of full-length thymosin beta-4.

A blend raises questions that studies of individual ingredients cannot answer. How do the peptides interact? Does the mixture remain stable? Do the ratios in products for sale match any tested formulation? Claims that GLOW improves skin, recovery, or tissue repair extend beyond the published evidence discussed here. That research does not establish such a clinical benefit for the blend.

FDA status of GLOW and KLOW ingredients

This section concerns the United States and was checked on October 31, 2026. Drug approval, inclusion on a compounding list, and enforcement discretion are separate decisions. None of these four peptides appears on the final 503A bulk substances list checked for this article. The FDA nomination list dated May 14, 2026, does not place their injectable forms in Category 1. But that older list is not the whole current picture: HHS announced a separate peptide enforcement-discretion policy on October 30. Compounded drugs remain unapproved medicines. Source Source

BPC-157, TB-500, injectable GHK-Cu, and KPV were among substances whose compounding nominations were withdrawn. The FDA’s safety-risk page explains that withdrawn nominations were removed from the Category 2 list; removal for that procedural reason does not resolve the underlying safety questions. The original regulatory account also cites Orrick’s report on the April 15, 2026 announcement and the subsequent April changes. That report is background commentary, not an authorization to compound. Source Source

Removal from Category 2 did not itself establish safety or eligibility for compounding. The May 14 nomination list remains a dated record, distinct from the final list and the October policy. The October 30 Federal Register notice describes a draft, nonbinding enforcement policy covering specified substances while rulemaking continues. The accompanying document sets conditions including a patient-specific prescription, verified manufacturing and testing, adverse-event reporting, defined substance identity and route, and only one active pharmaceutical ingredient. GLOW and KLOW contain several active ingredients, so they fall outside that single-ingredient condition. Source Source

What is different about GHK-Cu and KPV?

For GHK-Cu, the route of administration matters. The FDA’s nomination list places GHK-Cu in Category 1 except for injectable routes. The injectable nomination was withdrawn. This distinguishes a topical GHK-Cu product from an injectable GLOW or KLOW blend, but Category 1 means a substance is under evaluation under an interim policy; it is not FDA approval of a finished product. The practical and regulatory use of topical products is outside this article’s scope. Source

The FDA’s Pharmacy Compounding Advisory Committee considered BPC-157, KPV, and TB-500 at its July 23–24, 2026 meeting. The FDA meeting page confirms the agenda and explains that committee recommendations are nonbinding. The cited law firm’s report describes votes of 8 to 6, with one abstention, in favor of adding each substance to the bulk list. Those reported vote totals are secondary reporting; they are not a final FDA decision or proof of clinical benefit. Source Source

The October policy lists BPC-157, KPV, and TB-500 among six substances, but not GHK-Cu. Appendix B specifies acetate forms and permitted routes; for KPV it describes oral and topical forms, not injection. Thus it cannot be treated as permission for an injectable KLOW blend. Enforcement discretion is neither drug approval nor addition to the final bulk list, and the draft notice creates no binding right. Separately, FDA announced another advisory meeting before the end of February 2027, including consideration of GHK-Cu. That meeting date is not a deadline for approval. Source Source

Products marketed as GLOW or KLOW may be labeled for research use only or “not for human use.” Neither label guarantees purity, ingredient content, or sterility. The research discussed here does not establish those properties for any product being sold, and these blends are not FDA-approved medicines.

Important safety information

GLOW and KLOW are not FDA-approved treatments. Research-use labeling does not make an injectable blend suitable for use in people.

GLOW contains GHK-Cu, BPC-157, and TB-500; KLOW adds KPV. Research on these ingredients is preliminary and largely based on cell cultures and animal studies. The cited literature contains no clinical trial of either complete blend, so their safety and effectiveness in humans remain unestablished.

Preliminary findings cannot guarantee safety or effectiveness. Purity, ingredient content, and sterility may also be uncertain when products come from unregulated supply chains. This article is educational, not medical advice. Discuss health questions with a qualified healthcare professional.

Frequently asked questions

What is the GLOW peptide?

GLOW is an injectable blend of GHK-Cu, BPC-157, and TB-500, rather than a single peptide. It is marketed in the research-chemical sector and is not an FDA-approved medicine. The literature cited here contains no human trial of the complete blend.

What is the difference between GLOW and KLOW?

KLOW adds KPV to GLOW. That gives KLOW four peptides and GLOW three; GHK-Cu, BPC-157, and TB-500 are shared by both. The research discussed here includes no human trial of either complete mixture.

Is GLOW the same as GHK-Cu?

No. GHK-Cu is one of GLOW’s three ingredients: a copper-bound tripeptide with a long research history, mostly in cells and animals. GLOW also contains BPC-157 and TB-500. Each has its own body of research, also predominantly preclinical.

Is the GLOW peptide FDA-approved?

No. GLOW is not an FDA-approved medicine. The FDA nomination list dated May 14, 2026, does not place these injectable ingredients in Category 1, and they are absent from the final 503A bulk list checked for this article. The separate October 2026 HHS policy concerns certain single-ingredient products under conditions; it does not approve GLOW or extend its single-ingredient scope to a blend. Source

Can doctors prescribe GLOW or KLOW?

A prescription alone does not establish that a blend meets US compounding requirements. The May 14, 2026 FDA nomination list is only one part of the picture. HHS subsequently described conditional enforcement discretion for certain single-ingredient peptide products. GLOW and KLOW contain multiple active ingredients and therefore do not meet that policy’s single-ingredient condition. A clinician and pharmacist must check current federal and state requirements for the actual formulation. Source Source

Research-use products may carry a “not for human use” label; that label does not authorize clinical use. This discussion concerns the specified US framework and does not settle prescribing law in other countries.

Has the FDA reviewed BPC-157, TB-500, and KPV?

Yes, the FDA advisory committee considered all three at its July 23–24, 2026 meeting. The cited law firm reports 8-to-6 votes, with one abstention each, favoring inclusion. HHS subsequently issued an enforcement-discretion policy for certain single-ingredient products under specified conditions. Neither the advisory votes nor that policy amounts to FDA drug approval, and the final bulk-list rulemaking is a separate process. Source

Is there human research on GLOW?

The sources cited here contain no human investigation of the complete GLOW blend. There are limited clinical data on individual ingredients or related substances: small topical GHK-Cu skin studies, an uncontrolled BPC-157 knee-injection report with 16 telephone respondents—four of whom also received thymosin beta-4—and eye-drop studies of full-length thymosin beta-4. The full protein is not the same as the TB-500 fragment. None of these studies establishes the effects of GLOW or KLOW as a complete mixture. Source

Can blood tests show whether GLOW is working?

Routine blood tests cannot reliably show that GLOW is working. Each test measures a particular biomarker, and none of the standard markers discussed here is established as a direct measure of peptide benefit. Baseline liver and kidney tests, blood counts, and inflammation markers describe aspects of health. Their meaning for an individual is best assessed with a clinician.

This article provides information and education about experimental peptide blends and their evidence. It does not replace medical advice, diagnosis, or treatment. FDA advisory discussions and compounding nominations do not make GLOW or KLOW approved medicines. A qualified healthcare professional can help assess health concerns and established treatment options.

References

  1. Pickart L, Thayer L, Thaler MM (1973). A synthetic tripeptide which increases survival of normal liver cells, and stimulates growth in hepatoma cells. Biochemical and biophysical research communications, 54(2), 562-6. https://doi.org/10.1016/0006-291x(73)91459-9. PubMed

  2. Pickart L (2008). The human tri-peptide GHK and tissue remodeling. Journal of biomaterials science. Polymer edition, 19(8), 969-88. https://doi.org/10.1163/156856208784909435. PubMed

  3. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of clinical investigation, 92(5), 2368-76. https://doi.org/10.1172/JCI116842. PubMed

  4. Canapp SO, Farese JP, Schultz GS, Gowda S, Ishak AM, Swaim SF, Vangilder J, Lee-Ambrose L, Martin FG (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary surgery : VS, 32(6), 515-23. https://doi.org/10.1111/j.1532-950x.2003.00515.x. PubMed

  5. Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International journal of molecular sciences, 19(7). https://doi.org/10.3390/ijms19071987. PubMed

  6. Miller TR, Wagner JD, Baack BR, Eisbach KJ (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of facial plastic surgery, 8(4), 252-9. https://doi.org/10.1001/archfaci.8.4.252. PubMed

  7. Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR (2025). Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts : BI, 15, 30071. https://doi.org/10.34172/bi.30071. PubMed

  8. Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, Rotkvic I, Jagic V, Duvnjak M, Mise S (1994). The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides. Life sciences, 54(5), PL63-8. https://doi.org/10.1016/0024-3205(94)00796-9. PubMed

  9. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Turković B, Jagić V, Mildner B, Duvnjak M (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of physiology, Paris, 87(5), 313-27. https://doi.org/10.1016/0928-4257(93)90038-u. PubMed

  10. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific reports, 10(1), 17078. https://doi.org/10.1038/s41598-020-74022-y. PubMed

  11. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of molecular medicine (Berlin, Germany), 95(3), 323-333. https://doi.org/10.1007/s00109-016-1488-y. PubMed

  12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 110(3), 774-80. https://doi.org/10.1152/japplphysiol.00945.2010. PubMed

  13. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 21(4), 15563316251355551. https://doi.org/10.1177/15563316251355551. PubMed

  14. Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative therapies in health and medicine, 27(4), 8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/

  15. Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and tissue research, 377(2), 153-159. https://doi.org/10.1007/s00441-019-03016-8. PubMed

  16. Goldstein AL, Hannappel E, Kleinman HK (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in molecular medicine, 11(9), 421-9. https://doi.org/10.1016/j.molmed.2005.07.004. PubMed

  17. Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of chromatography. A, 1265, 57-69. https://doi.org/10.1016/j.chroma.2012.09.043. PubMed

  18. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug testing and analysis, 4(9), 733-8. https://doi.org/10.1002/dta.1402. PubMed

  19. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 11(1), 19-24. https://doi.org/10.1046/j.1524-475x.2003.11105.x. PubMed

  20. Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 24(7), 2144-51. https://doi.org/10.1096/fj.09-142307. PubMed

  21. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466-72. https://doi.org/10.1038/nature03000. PubMed

  22. Hinkel R, Ball HL, DiMaio JM, Shrivastava S, Thatcher JE, Singh AN, Sun X, Faskerti G, Olson EN, Kupatt C, Bock-Marquette I (2015). C-terminal variable AGES domain of Thymosin β4: the molecule’s primary contribution in support of post-ischemic cardiac function and repair. Journal of molecular and cellular cardiology, 87, 113-25. https://doi.org/10.1016/j.yjmcc.2015.07.004. PubMed

  23. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International journal of molecular sciences, 24(1). https://doi.org/10.3390/ijms24010554. PubMed

  24. Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr (2026). Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American journal of sports medicine, 3635465261464420. https://doi.org/10.1177/03635465261464420. PubMed

  25. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 37(3), 822-837. https://doi.org/10.52312/jdrs.2026.2951. PubMed

  26. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

  27. Orrick. (2026, April). FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings. https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings

  28. U.S. Food and Drug Administration. (2026). Bulk drug substances nominated for use in compounding under section 503A (updated May 14, 2026). https://www.fda.gov/media/94155/download

  29. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

  30. McDermott Will & Schulte. (2026, July 27). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/

  31. U.S. Food and Drug Administration. (n.d.). Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee

  32. Electronic Code of Federal Regulations. 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23

  33. Department of Health and Human Services (2026, October 30). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 91, 68526–68527. https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm

  34. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf